Ethicon seals Omrix deal
This article was originally published in The Gray Sheet
Wound management division of J&J unit gains exclusive North American marketing and distribution rights for Crosseal fibrin sealant from Belgian firm Omrix Biopharmaceuticals, adding to an exclusive European pact from June 2003. The first non-bovine sealant to launch in the U.S., Crosseal originally was cleared via biologics license application in March 2003 for use as an adjunct to hemostasis in liver surgery patients. Ethicon notes the device has a triple lumen delivery mechanism that does not mix the human thrombin and biological active component until they reach the tip - a feature that may prevent clogging seen in other sealants. Baxter's Tisseel uses aprotinin, a protein derived from cow lungs, and is Crosseal's chief competitor (1"The Gray Sheet" July 28, 2003, p. 16)...
You may also be interested in...
American Red Cross Plasma Services' three U.S. distributors will ship Omrix Biopharmaceuticals' Crosseal fibrin sealant to liver surgeons throughout the summer
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.